Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents
Expert Opinion on Drug Safety August 15, 2023 DOI: 10.1080/14740338.2023.2248883 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | LSD Psilocybin Serotonin |
| Keywords | Agonism 5-HT Receptor Pharmacology Serotonin antagonists Hallucinogen |
| Citations | 26 |
| Key points | Psilocybin, LSD, and ecstasy may pose a risk of valvular heart disease via 5HT2B receptor agonism, as noted in FDA guidance. |
Abstract
KEYWORDS: PsilocybinLysergic acid diethylamide (LSD)ecstasyvalvular heart disease5HT2B receptor agonismFDA guidance
Citations in the library
Cited by 23
- A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics Biology October 28, 2023
- Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research. American Journal of Psychiatry 2025
- Do the therapeutic effects of psilocybin involve actions in the gut? TIPS - Trends in Pharmacological Sciences February 1, 2024
- Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue Life December 15, 2023
- Effects of hallucinogenic drugs on the human heart Frontiers in Pharmacology February 2, 2024
and 18 more in the library
Cites 11
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies Acta Psychiatrica Scandinavica October 30, 2020
- Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression CNS Drugs November 17, 2021
- MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. FOCUS: The Journal of Lifelong Learning in Psychiatry July 1, 2023
- SAR of psilocybin analogs: Discovery of a selective 5-HT2C agonist Bioorganic & Medicinal Chemistry Letters August 3, 2005
and 6 more in the library